GASTRORETENTIVE FLOATING TECHNOLOGY FOR ERADICATION OF HELICOBACTER PYLORI: AN INSIGHT VIEW
DOI:
https://doi.org/10.22159/ijap.2021v13i3.39369Keywords:
Helicobacter pylori, Gastric ulcer, Pharmacotherapeutic vistas, Gastroretentive technology, Floating dosage formsAbstract
Helicobacter pylori is a virulent human pathogen infecting about 50% of the population worldwide. Being a leading cause of gastric ulcer, duodenal ulcer, gastritis, dyspepsia, gastric tumorigenesis etc., this organism has been the focus of concerted study to establish uncertainty of its genetics, immunopathogenesis and cell biology. Scientists have tried to effectively eradicate this pathogen from the gastrointestinal tract in various manners. Inquest of this venture, gastroretentive drug delivery systems including floating dosage forms have emerged as a boon and offer significantly improved therapeutic effects of different antimicrobial drugs. This article presents an evocative review of the structural features, epidemiological evidences and various pharmacotherapeutics vistas. In addition, various novel gastroretentive dosage forms developed so far to combat Helicobacter pylori infection are also discussed. Comprehensive literature review has been performed for this manuscript by utilizing relevant databases like PubMed, SCOPUS, Web of Science, Science Direct, Google Scholar etc., from 1997 up to the year 2020.
Downloads
References
Proenca Modena JL, Acrani GO, Brocchi M. Helicobacter pylori: phenotypes, genotypes and virulence genes. Future Microbiol 2009;4:223-40.
Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of the acute coronary syndrome: a systematic review and meta-analysis. Medicine 2019;98:18348-59.
Kang SJ, Kim DH, Lee BJ. NMR study on small proteins from Helicobacter pylori for antibiotic target discovery: a review. Molecules 2013;18:13410-24.
Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720-41.
Bridge DR, Merrell DS. Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease. Gut Microbes 2013;4:101-17.
Lee DS, Moss SF. Targeting Helicobacter pylori in gastric carcinogenesis. Expert Opin Ther Targets 2007;11:757-69.
Herszenyi L, Bakucz T, Barabás L, Tulassay Z. Pharmacological approach to gastric acid suppression: past, present, and future. Dig Dis 2020;38:104-11.
Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 2007;12:89-102.
Torres J, Perez GP, Ximenez C, Munoz L, Camorlinga Ponce M, Ramos F, et al. The association of intestinal parasitosis and H. pylori infection in children and adults from a mexican community with a high prevalence of parasitosis. Helicobacter 2003;8:179-85.
Kumar S, Kumar A, Dixit VK. Evidences showing association of interleukin-1B polymorphisms with increased risk of gastric cancer in an Indian population. Biochem Biophys Res Commun 2009;387:456-60.
Lai FP, Tu YF, Sheu BS, Yang YJ. Maternal H. pylori seropositivity is associated with gestational hypertension but is irrelevant to fetal growth and development in early childhood. BMC Pediatr 2019;19:501-10.
Pachathundikandi SK, Tegtmeyer N, Arnold IC, Lind J, Neddermann M, Falkeis-Veits C, et al. T4SS-dependent TLR5 activation by Helicobacter pylori infection. Nat Commun 2019;10:1-11.
Umamaheshwari RB, Jain NK. Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. J Controlled Release 2004;99:27-40.
Ben Mansour K, Fendri C, Battikh H, Garnier M, Zribi M, Jlizi A, et al. Multiple and mixed Helicobacter pylori infections: comparison of two epidemiological situations in tunisia and france. Infect Genet Evol 2016;37:43-8.
Bazzoli F, Bianchi Porro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 2002;34:70-83.
Egemen A, Yilmaz O, Akil I, Altuglu I. Evaluation of association between hepatitis a and Helicobacter pylori infections and routes of transmission. Turk J Pediatr 2006;48:135-9.
Cardenas VM, Boller F, Roman GC. Helicobacter pylori, vascular risk factors and cognition in US older adults. Brain Sci 2019;9:370-86.
Shinmura T, Adachi K, Yamaguchi Y, Izawa S, Hijikata Y, Ebi M. Vonoprazan-based triple-therapy could improve the efficacy of the tailored therapy of Helicobacter pylori infection. J Gastrointestin Liver Dis 2019;28:389-95.
Annibale B, Capurso G, Delle Fave G. Consequences of Helicobacter pylori infection on the absorption of micronutrients. Dig Liver Dis 2002;341:72-7.
Vollaard AM, Verspaget HW, Ali S, Visser LG, Veenendaal RA, Van Asten HA, et al. Helicobacter pylori infection and typhoid fever in Jakarta, Indonesia. Epidemiol Infect 2006;134:163-70.
Shinohara K, Miyazaki K, Noda N, Saitoh D, Terada M, Wakasugi H. Gastric diseases related to Helicobacter pylori and epstein barr virus infection. Microbiol Immunol 1998;42:415-21.
De Falco M, Lucariello A, Iaquinto S, Esposito V, Guerra G, De Luca A. Molecular mechanisms of Helicobacter pylori pathogenesis. J Cell Physiol 2015;230:1702-7.
Kim A, Servetas SL, Kang J, Kim J, Jang S, Choi YH, et al. Helicobacter pylori outer membrane protein, HomC, shows geographic dependent polymorphism that is influenced by the Bab family. J Microbiol 2016;54:846-52.
Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit Rev Microbiol 2018;44:1-22.
Bin Saeed AA. Is there a link between seropositivity to Helicobacter pylori and hepatitis A virus? a systematic review. Int J Infect Dis 2010;14:567-71.
Gonzalez A, Casado J, Chueca E, Salillas S, Velazquez Campoy A, Espinosa Angarica V, et al. Repurposing dihydropyridines for treatment of Helicobacter pylori infection. Pharmaceutics 2019;11:681-99.
Backert S, Neddermann M, Maubach G, Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2016;21:19-25.
De Bernard M, Josenhans C. Pathogenesis of Helicobacter pylori infection. Helicobacter 2014;19:11-8.
Greenfield LK, Jones NL. Modulation of autophagy by Helicobacter pylori and its role in gastric carcinogenesis. Trends Microbiol 2013;21:602-12.
Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter 2017;22:1-5.
Cid TP, Fernandez MC, Benito Martinez S, Jones NL. Pathogenesis of Helicobacter pylori infection. Helicobacter 2013;18:12-7.
Chang WL, Yeh YC, Sheu BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci 2018;25:68-77.
Zhang Y, Zhou X, Zhang Q, Zhang Y, Wang X. Involvement of NF-κ B signaling pathway in the regulation of PRKAA1-mediated tumorigenesis in gastric cancer tumorigenesis in gastric cancer. Artif Cells Nanomed Biotechnol 2019;47:3677-86.
Atherton JC, Blaser JM. Coadaptation of Helicobacter pylori and humans ancient history, modern implications. J Clin Invest 2009;119:2475-87.
Queralt N, Araujo R. Analysis of the survival of H. pylori within a laboratory-based aquatic model system using molecular and classical techniques. Microb Ecol 2007;54:771-7.
Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in japan. J Gastroenterol 2007;42:1-15.
Algood HMS, Cover TL. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev 2006;19:597-613.
Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90.
Adebisi AO, Conway BR. Modification of drug delivery to improve antibiotic targeting to the stomach. Ther Delivery 2015;6:741-62.
Rico MR, Moreno Y, Barat JM. In vitro antimicrobial activity of immobilised essential oil components against Helicobacter pylori. World J Microbiol Biotechnol 2020;36:1-9.
Kiesslich R, Goetz M, Burg J, Stolte M, Siegel E, Maeurer MJ, et al. Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. Gastroenterology 2005;128:2119-23.
Dzierzanowska Fangrat K, Lehours P, Megraud F, Dzierzanowska D. Diagnosis of Helicobacter pylori infection. Helicobacter 2006;11:6-13.
Pahwa R, Nath A, Sharma PC, Kumar V, Kohli K. Impact of Helicobacter pylori on the prevalence of gastroduodenal diseases. Drug Invent Today 2010;2:258-63.
De Boer WA, Tytgat GNJ. Treatment of Helicobacter pylori infection. Br Med J 2000;320:31-4.
Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol 2015;21:10644-53.
Charoenying T, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Akkaramongkolporn P, Opanasopit P. Fabrication of floating capsule-in-3D-printed devices as gastro-retentive delivery systems of amoxicillin. J Drug Delivery Sci Technol 2020;55:101393.
Chey WD, Wong BC. American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
Harris A. Treatment of Helicobacter pylori. World J Gastroenterol 2001;7:303-7.
Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol 2007;21:315-24.
Van der Hulst R W M, Van der Ende A, Homan A, Roorda P, Dankert J, Tytgat G. Influence of metronidazole resistance on the efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998;42:166-9.
Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000;14:91-5.
Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des 2005;11:775-90.
Verma A, Dubey J, Hegde RR, Rastogi V, Pandit JK. Helicobacter pylori: past, current, future treatment strategies with gasrtoretentive drug delivery systems. J Drug Targeting 2016;24:897-915.
Berthenet E, Sheppard S, Vale FF. Recent "omics" advances in Helicobacter pylori. Helicobacter 2016;21:14-8.
Yanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, Zhang S, et al. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res 2009;2:353-60.
Han YM, Park JM, Lee D, Oh JY, Hahm KB. Korean probiotic kimchi prevented Helicobacter pylori-associated gastric cancer in mice and human. FASEB J 2017;31:1067-71.
Kumar M, Kaushik D. An overview on various approaches and recent patents on gastroretentive drug delivery systems. Recent Pat Drug Delivery Formulation 2018;12:84-92.
Adibkia K, Hamedeyazdan S, Javadzadeh Y. Drug release kinetics and physicochemical characteristics of floating drug delivery systems. Expert Opin Drug Delivery 2011;8:891-903.
Wu Y, Zhang W, Huang J, Luo Z, Li J, Wang L. Mucoadhesive improvement of alginate microspheres as potential gastroretentive delivery carrier by blending with bletilla striata polysaccharide. Int J Biol Macromol 2020;156:1191-201.
Kotreka UK, Adeyeye MC. Gastroretentive floating drug-delivery systems: a critical review. Crit Rev Ther Drug Carrier Syst 2011;28:47-99.
El Nabarawi MA, Teaima MH, El-Monem RAA, El Nabarawy NA, Gaber DA. Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of mebeverine HCl. Drug Des Dev Ther 2017;11:1081-93.
Pahwa R, Bisht S, Kumar V, Kohli K. Recent advances in gastric floating drug delivery technology: a review. Curr Drug Delivery 2013;10:286-98.
Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Controlled Release 2003;90:143-62.
Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: a recent update. Asian J Pharm Sci 2016;11:575-84.
Soni H, Ghulaxe C, Upadhyay S, Pillai S. Development and in vitro evaluation of an oral floating tablet of metronidazole. J Drug Delivery Ther 2018;8:83-6.
Sheikh FA, Hussain MA, Ashraf MU, Haseeb MT, Farid-ul-Haq M. Linseed hydrogel-based floating drug delivery system for fluoroquinolone: design, in vitro drug release and in vivo real-time floating detection. Saudi Pharm J 2020;28:538-49.
Pahwa R, Singh M, Kumar V, Kohli K. Recent advances and patent perspectives in gastroretentive technology. Recent Pat Drug Delivery Formulation 2012;6:278-90.
Schneider F, Koziolek M, Weitschies W. In vitro and in vivo test methods for the evaluation of gastroretentive dosage forms. Pharmaceutics 2019;11:416-45.
Awasthi R, Kulkarni GT. Decades of research in drug targeting to the upper gastrointestinal tract using gastro retention technologies: where do we stand? Drug Delivery 2016;23:378-94.
Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004;277:141-53.
Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm 2016;510:144-58.
Sopyan I, Sriwidodo, Wahyuningrum R, Aliza PN. A review: floating drug delivery system as a tool to improve dissolution rate in gastric. Int J Appl Pharm 2020;12:10-3.
Ghoneim AM, Tadros MI, Alaa-Eldin AA. Spray-dried silica xerogel nanoparticles as a promising gastroretentive carrier system for the management of chemotherapy-induced nausea and vomiting. Int J Nanomed 2019;14:9619-30.
Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: targeted gastro-retentive drug delivery systems. J Drug Targeting 2015;23:109-24.
Mohapatra PR, Satyavani CH, Sahoo S. Design and development of carvedilol gastroretentive floating drug delivery systems using hydrophilic polymers and in vitro characterization. Int J Pharm Pharm Sci 2020;12:66-73.
Chen R, Guo X, Liu X, Cui H, Wang R, Han J. Formulation and statistical optimization of gastric floating alginate/oil/chitosan capsules loading procyanidins: in vitro and in vivo evaluations. Int J Biol Macromol 2018;108:1082-91.
Vasvari G, Haimhoffer A, Horvath L, Budai I, Trencsenyi G, Beresova M. Development and characterization of gastroretentive solid dosage form based on melt foaming. AAPS PharmSciTech 2019;20:1-11.
Mirani AG, Patankar SP, Kadam VJ. Risk-based approach for systematic development of gastroretentive drug delivery system. Drug Delivery Transl Res 2016;6:579-96.
Zhao S, Lv Y, Zhang J Bin, Wang B, Lv GJ, Ma XJ. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori. World J Gastroenterol 2014;20:9321-9.
Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration. Expert Opin Drug Delivery 2012;9:551-65.
Ishak RAH. Buoyancy-generating agents for stomach-specific drug delivery: an overview with special emphasis on floating behavior. J Pharm Pharm Sci 2015;18:77-100.
Raviteja G, Narayana RKVV, Baskaran M, Meghana G, Ganesh G. A mucoadhesive gastroretentive dosage form for valacyclovir. Int J Pharm Pharm Sci 2014;6:422-7.
Simons FJ, Wagner KG. Modeling, design and manufacture of innovative floating gastroretentive drug delivery systems based on hot-melt extruded tubes. Eur J Pharm Biopharm 2019;137:196-208.
Du F, Wu Y, Du F, Zhang L, Feng W, Zhao L. Construction of catechol-grafted chitosan alginate/barium sulfate microcapsules for computed tomography real-time imaging and gastroretentive drug delivery. Int J Nanomed 2019;14:6001-18.
Prajapati ST, Patel LD, Patel CN. Polymers for floating drug delivery system. Syst Rev Pharm 2011;2:1-7.
Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Controlled Release 2006;111:1-18.
Melocchi A, Uboldi M, Inverardi N, Briatico Vangosa F, Baldi F, Pandini S. Expandable drug delivery system for gastric retention based on shape memory polymers: development via 4D printing and extrusion. Int J Pharm 2019;571:118700.
Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Controlled Release 2000;63:235-59.
Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics 2019;11:1-22.
Adebisi A, Conway BR. Gastroretentive microparticles for drug delivery applications. J Microencapsulation 2011;28:689-708.
Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 2006;6:501-8.
Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems: a review. Asian J Pharm Clin Res 2010;3:2-10.
Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Delivery 2011;18:97-110.
Murphy C, Pillay V, Choonara Y, Du Toit L. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. Curr Drug Delivery 2009;6:451-60.
Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming system-an upcoming approach of gastroretentive drug delivery system. J Controlled Release 2013;168:151-65.
Pahwa R, Saini N, Kumar V, Kohli K. Chitosan-based gastroretentive floating drug delivery technology: an updated review. Expert Opin Drug Delivery 2012;9:525-39.
Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm 2004;30:1019-28.
Sathish D, Himabindu S, Shravan Kumar Y, Shayeda, Madhusudan Rao Y. Floating drug delivery systems for prolonging gastric residence time: a review. Curr Drug Delivery 2011;8:494-510.
Bera H, Maiti S, Saha S, Nayak AK. Biopolymers-based gastroretentive buoyant systems for therapeutic management of Helicobacter pylori infection. Polysaccharide Carriers Drug Delivery 2019;713-36. DOI:10.1016/B978-0-08-102553-6.00024-6
Pahwa R, Jindal S, Chhabra L, Dutt H, Rao R. Development and in vitro characterization of effervescent floating drug delivery system of famotidine. Int J Pharm Sci Res 2012;3:241-6.
Li Z, Zeng R, Yang L, Ren X, Maffucci KG, Qu Y. Development and characterization of PCL electrospun membrane-coated Bletilla striata polysaccharide-based gastroretentive drug delivery system. AAPS PharmSciTech 2020;21:1-14.
Dey SK, De PK, De A, Ojha S, De R, Mukhopadhyay AK, et al. Floating muco adhesive alginate beads of amoxicillin trihydrate: a facile approach for H. pylori eradication. Int J Biol Macromol 2016;89:622-31.
El Mahrouk GM, Abouleinien MH, Makhlouf AI. Design, optimization and evaluation of novel metronidazole loaded gastroretentive pH sensitive hydrogel. AAPS PharmSciTech 2016;17:1285-97.
Rossi A, Conti C, Colombo G, Castrati L, Scarpignato C, Barata P, et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Dev Ind Pharm 2016;42:332-9.
Thombre NA, Gide PS. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication. Drug Delivery 2016;23:405-19.
Adebisi AO, Laity PR, Conway BR. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori. J Pharm Pharmacol 2015;67:511-24.
Aoki H, Iwao Y, Mizoguchi M, Noguchi S, Itai S. Clarithromycin highly-loaded gastro floating fine granules prepared by high-shear melt granulation can enhance the efficacy of Helicobacter pylori eradication. Eur J Pharm Biopharm 2015;92:22-7.
Ugurlu T, Karacicek U, Rayaman E. Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. Acta Pol Pharm 2014;71:311-21.
Gattani SG, Savaliya PJ, Belgamwar VS. Floating mucoadhesive beads of clarithromycin for the treatment of Helicobacter pylori infection. Chem Pharm Bull 2010;58:782-7.
Javadzadeh Y, Hamedeyazdan S, Adibkia K, Kiafar F, Zarrintan MH, Barzegar-Jalali M. Evaluation of drug release kinetics and physico-chemical characteristics of metronidazole floating beads based on calcium silicate and gas-forming agents. Pharm Dev Technol 2010;15:329-38.
Rajinikanth PS, Mishra B. Stomach site specific drug delivery system of clarithromycin for eradication of Helicobacter pylori. Chem Pharm Bull 2009;57:1068-75.
Badhan AC, Mashru RC, Shah PP, Thakkar AR, Dobaria NB. Development and evaluation of sustained release gastroretentive minimatrices for effective treatment of H. pylori infection. AAPS PharmSciTech 2009;10:459-67.
Jain SK, Jangdey MS. Lectin conjugated gastroretentive multiparticulate delivery system of clarithromycin for the effective treatment of Helicobacter pylori. Mol Pharmaceutics 2009;6:295-304.
Rajinikanth PS, Mishra B. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H. pylori. J Controlled Release 2008;125:33-41.
Rajinikanth PS, Mishra B. Floating in situ gelling system of acetohydroxamic acid for clearance of H. pylori. Drug Dev Ind Pharm 2008;34:577-87.
Ishak RA, Awad GA, Mortada ND, Nour SA. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy. J Controlled Release 2007;119:207-14.
Rajinikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int J Pharm 2007;335:114-22.
Rajinikanth PS, Mishra B. Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm 2007;57:413-27.
Patel JK, Patel MM. Stomach specific anti-Helicobacter pylori therapy: preparation and evaluation of amoxicillin-loaded chitosan mucoadhesive microspheres. Curr Drug Delivery 2007;4:41-50.
Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur J Pharm Sci 2005;24:363-73.
Umamaheshwari RB, Jain S, Bhadra D, Jain NK. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J Pharm Pharmacol 2003;55:1607-13.
Umamaheswari RB, Jain S, Tripathi PK, Agrawal GP, Jain NK. Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori. Drug Delivery 2002;9:223-31.
Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y, Shibata K, et al. Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pylori. Biol Pharm Bull 1999;22:55-60.
Yang L, Eshraghi J, Fassihi R. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Controlled Release 1999;57:215-22.
Published
How to Cite
Issue
Section
